Bifidobacterium breve для Irritable Bowel Syndrome (IBS)

Q: Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?

Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).

Q: How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?

Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.

Q: Are there side effects of Bifidobacterium breve?

Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

Q: How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?

We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.

Limited data from small studies. Preliminary evidence for symptom improvement.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dbreve\u0026condition\u003Dibs'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Итог

Limited data from small studies. Preliminary evidence for symptom improvement.

Key Study Findings

Review

Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases.

Dose: None или: None Outcome: None Эффект: None None

Популяция: None

Other n=1098 8 weeks Open-label

A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of …

Dose: None или: None (single-arm open-label) Outcome: Treatment success for abdominal pain and bloating Эффект: 73% pain, 81.9% bloating success at T1 <0.001

Популяция: IBS patients from 52 Italian gastroenterologists

Randomized Controlled Trial n=61 8 weeks Double-blind

Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with …

Dose: None или: Placebo Outcome: IBS-SSS symptom severity score change Эффект: None None

Популяция: Patients with moderate-severe diarrhea-predominant IBS

Randomized Controlled Trial 4 weeks

Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group …

Dose: 2 g или: Placebo Outcome: Constipation symptoms Эффект: None P = 0.005

Популяция: IBS patients

Review

Postbiotics: A new member in the biotics family.

Dose: None или: None Outcome: Clinical applications overview Эффект: None None

Популяция: General population (review)

In Vitro

Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal …

Dose: None или: None Outcome: Colitis severity Эффект: None None

Популяция: Crohn's disease patients

Key Statistics

Исследования

150

Участники

↑

Positive

Оценка

Referenced Papers

Compendium of Bifidobacterium-based probiotics: characteristics and therapeutic impact on human diseases. Review

Microbiome research reports 2025 16 цитирований

A multicenter real-world, open-label study assessing the impact of a probiotic mixture on symptoms of irritable bowel syndrome in adults. Other

Beneficial microbes 2025

Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results … Other

Frontiers in nutrition 2025

Bowel Inflammation and Nutrient Supplementation: Effects of a Fixed Combination of Probiotics, Vitamins, and Herbal Extracts in an In Vitro … Other

The Yale journal … 2024 5 цитирований

Efficacy of Quadruple-coated Probiotics in Patients With Irritable Bowel Syndrome: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study. Other

Journal of neurogastroenterology … 2024 4 цитирований

Postbiotics: A new member in the biotics family. Other

Archivos argentinos de … 2024 3 цитирований

Gut Microbiome Alterations Following Oral Serum-Derived Bovine Immunoglobulin Administration in the Management of Dysbiosis. Other

Cureus 2024 1 цитирований

Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data. Other

Journal of translational … 2023 30 цитирований

Dose-Response Efficacy and Mechanisms of Orally Administered Bifidobacterium breve CCFM683 on IMQ-Induced Psoriasis in Mice. Other

Nutrients 2023 19 цитирований

Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: … Other

Journal of neurogastroenterology … 2022 21 цитирований

Immunomodulatory Effects of Bifidobacterium spp. and Use of Bifidobacterium breve and Bifidobacterium longum on Acute Diarrhea in Children. Other

Journal of microbiology … 2022 15 цитирований

Serpin-positive Bifidobacterium breve CNCM I-5644 improves intestinal permeability in two models of irritable bowel syndrome. Other

Scientific reports 2022 14 цитирований

Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review. Systematic Review

Journal of clinical … 2018 34 цитирований

Effect of administering a multi-species probiotic mixture on the changes in fecal microbiota and symptoms of irritable bowel syndrome: a … Other

Journal of clinical … 2015 62 цитирований

Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Meta-Analysis

Revista espanola de … 2013 102 цитирований

The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, … RCT

Journal of clinical … 2012 207 цитирований

Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in the maternal separation model of irritable bowel … Other

PloS one 2012 31 цитирований

BDNF expression in the hippocampus of maternally separated rats: does Bifidobacterium breve 6330 alter BDNF levels? Other

Beneficial microbes 2011 89 цитирований

The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Other

Neurogastroenterology and motility 2010 213 цитирований

Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. RCT

BMC gastroenterology 2010 91 цитирований

Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. RCT

Alimentary pharmacology & … 2007 102 цитирований

Clinical studies on alleviating the symptoms of irritable bowel syndrome. RCT

Asia Pacific journal … 2006

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. RCT

Alimentary pharmacology & … 2005 398 цитирований

Probiotics in the treatment of irritable bowel syndrome. RCT

Journal of clinical … 2004 205 цитирований

Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome … Other

Research in microbiology 2001 201 цитирований

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Часто используемые дозировки

general:: 1-10 billion CFU/day
adultgisupport:: 5-10 billion CFU/day
neonatalsupport:: 1-5 billion CFU/day (as directed by pediatrician)

Верхний предел: Well-tolerated up to 10 billion CFU/day in clinical trials

Дозировки, изученные в исследованиях

Дозировка	Длительность	Эффект	N
None	--	Mixed	--
None	8 weeks	Positive	1098
None	8 weeks	Neutral	61
2 g	4 weeks	Mixed	--
None	--	Positive	--
None	--	Positive	--
Serum-derived bovine immunoglobulin (SBI)	--	Positive	--
None	--	Positive	--

Лучшее время приёма: Before meals or on empty stomach; for infants, mix with breast milk or formula

Safety & Side Effects

Зарегистрированные побочные эффекты

⚠ Mild gas during initial use
⚠ Occasional loose stools in infants (transient)
⚠ Rare abdominal discomfort
⚠ Very rare: bacteremia in immunocompromised individuals

Известные взаимодействия

● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
● Immunosuppressants (use with caution in immunocompromised patients)

Допустимый верхний уровень потребления: Well-tolerated up to 10 billion CFU/day in clinical trials

Всегда консультируйтесь с врачом перед началом приёма любых добавок.Всегда консультируйтесь с лечащим врачом перед началом приёма любой добавки.

Frequently Asked Questions

Does Bifidobacterium breve help with Irritable Bowel Syndrome (IBS)?

Based on 2 studies with 150 participants, there is preliminary evidence that needs more research that Bifidobacterium breve may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is D (Very Early Research).

How much Bifidobacterium breve should I take for Irritable Bowel Syndrome (IBS)?

Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Bifidobacterium breve?

Reported side effects may include Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Bifidobacterium breve and Irritable Bowel Syndrome (IBS)?

We rate the evidence as Grade D (Very Early Research). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.

Related Evidence

Другие ингредиенты для Irritable Bowel Syndrome (IBS)

Peppermint Oil A Lactobacillus rhamnosus GG B Psyllium Husk B Lactobacillus plantarum B Partially Hydrolyzed Guar Gum (PHGG) B Bifidobacterium longum B

Краткий вывод

Limited data from small studies. Preliminary evidence for symptom improvement.

Evidence Strength30%

Low confidence

Разбор исследований

RCT (6)Meta (1)Other (0)

Сравнить альтернативы

Узнайте, как другие ингредиенты сравниваются при данном состоянии.

Посмотреть все ингредиенты для Irritable Bowel Syndrome (IBS)

Узнать больше

Отказ от ответственности FDA: Данные утверждения не были оценены Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA). Продукты и информация на этом сайте не предназначены для диагностики, лечения, излечения или профилактики каких-либо заболеваний. Представленные оценки доказательности основаны на нашем анализе опубликованных рецензируемых исследований и не являются медицинской консультацией. Всегда консультируйтесь с лечащим врачом перед началом приёма любых добавок.